Merck & Co., Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $281.26B |
| Revenue | $65.59B |
| Net Income | $8.94B |
| Total Assets | $128.69B |
| Net Assets | $45.88B |
| Employees | 73,000 |
| Value | |
| P/E | 31.48x |
| P/B | 6.13x |
| P/S | 4.29x |
| EV/EBITDA | 14.32x |
| FCF Yield | 5.02% |
| Profitability | |
| ROE | 19.48% |
| ROA | 6.94% |
| Op. Margin | 27.59% |
| Revenue Growth | 4.27% |
| Earnings Growth | -183.48% |
| Financial Health | |
| Debt Ratio | 180.38% |
| Total Debt | $49.12B |
| FCF | $14.12B |
| Cash | $5.33B |
| Current Ratio | 1.30x |
| Net Debt/EBITDA | 1.93x |
| Dividend | |
| Div. Yield | 2.93% |
| Div. Growth | 5.31% |
| Performance | |
| 1Y Return | 46.28% |
| 1M Return | -0.32% |
| From 52W High | -9.00% |
| 1Y MDD | -12.10% |
| Trading | |
| Volume | 11,617,920 shares |
| Trading Value | $1.32B |
| Per Share | |
| EPS | $7.33 |
| BPS | $21.13 |
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.